The effect of genotype on methotrexate polyglutamate variability in juvenile idiopathic arthritis and association with drug response

Arthritis and Rheumatism

Volumn 63, Issue 1, 2011, Pages 276-285

  Becker, Mara L ^a   Gaedigk, Roger ^a   Van Haandel, Leon ^b   Thomas, Bradley ^a   Lasky, Andrew ^a   Hoeltzel, Mark ^a   Dai, Hongying ^a   Stobaugh, John ^b   Leeder, J Steven ^a  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; LIVER ENZYME; METHOTREXATE POLYGLUTAMATE; PURINE; PYRIMIDINE;

ADOLESCENT; ADULT; ARTICLE; CELL TRANSFORMATION; CHILD; CROSS-SECTIONAL STUDY; DRUG RESPONSE; ERYTHROCYTE; FEMALE; GASTROINTESTINAL SYMPTOM; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; INFORMED CONSENT; ION PAIR CHROMATOGRAPHY; JUVENILE RHEUMATOID ARTHRITIS; LABORATORY TEST; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MEDICAL RECORD REVIEW; NEWBORN; PRIORITY JOURNAL; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; SCREENING TEST; SINGLE NUCLEOTIDE POLYMORPHISM; TERTIARY HEALTH CARE; TREATMENT RESPONSE;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; CLUSTER ANALYSIS; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MASS SPECTROMETRY; METHOTREXATE; POLYGLUTAMIC ACID; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME;

EID: 78650793942     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30080     Document Type: Article

References (29)

1. Cassidy JT, Petty RE, Laxer RM, Lindsley CB, editors. Textbook of pediatric rheumatology. 5th ed. Philadelphia: Elsevier Saunders; 2005.
2. Ortiz-Alvarez O, Morishita K, Avery G, Green J, Petty RE, Tucker LB, et al. Guidelines for blood test monitoring of methotrexate toxicity in juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2501-6.
3. Becker ML, Rose CD, Cron RQ, Sherry DD, Bilker WB, Lautenbach E,. Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of two initial dosing regimens. J Rheumatol 2010; 37: 870-5.
4. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, et al. Polyglutamation of methotrexate: is methotrexate a prodrug? J Clin Invest 1985; 76: 907-12.
5. Cronstein BN, Naime D, Ostad E,. The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675-82.
6. Allegra CJ, Chabner BA, Drake JC, Lutz R, Rodbard D, Jolivet J,. Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 1985; 260: 9720-6.
7. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004; 50: 2766-74.
8. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis 2005; 64: 1180-5.
9. Dervieux T, Greenstein N, Kremer J,. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum 2006; 54: 3095-103.
10. Schroder H, Fogh K,. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1988; 21: 145-9.
11. Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML,. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2008; 58: 3299-308.
12. Becker ML, van Haandel L, Gaedigk R, Lasky A, Hoeltzel M, Stobaugh J, et al. Analysis of intracellular methotrexate polyglutamates in patients with juvenile idiopathic arthritis: effect of route of administration on variability in intracellular methotrexate polyglutamate concentrations. Arthritis Rheum 2010; 62: 1803-12.
13. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2.
14. Van Haandel L, Becker ML, Leeder JS, Williams TD, Stobaugh JF,. A novel high-performance liquid chromatography/mass spectrometry method for improved selective and sensitive measurement of methotrexate polyglutamation status in human red blood cells. Rapid Commun Mass Spectrom 2009; 23: 3693-702.
15. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A,. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
16. Hahn LW, Ritchie MD, Moore JH,. Multifactor dimensionality reduction software for detecting gene-gene and gene- environment interactions. Bioinformatics 2003; 19: 376-82.
17. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A,. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
18. Ruperto N, Murray KJ, Gerloni V, Wulffraat N, de Oliveira SK, Falcini F, et al, for the Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191-201.
19. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V,. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum 2004; 50: 364-71.
20. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 1984-92.
21. Wallace CA, Sherry DD,. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992; 19: 1604-7.
22. Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN,. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate. J Rheumatol 2004; 31: 179-82.
23. Reiff A, Shaham B, Wood BP, Bernstein BH, Stanley P, Szer IS,. High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis. Clin Exp Rheumatol 1995; 13: 113-8.
24. Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Frampton C, James J, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. Arthritis Rheum 2009; 60: 2248-56.
25. Dervieux T, Kremer J, Lein DO, Capps R, Barham R, Meyer G, et al. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004; 14: 733-9.
26. Stamp LK, O'Donnell JL, Chapman PT, Zhang M, James J, Frampton C, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum 2010; 62: 359-68.
27. Hinks A, Moncrieffe H, Martin P, Lal SD, Ursu S, Kassoumeri L, et al. Genetic polymorphisms in key methotrexate (MTX) pathway genes associated with response to MTX treatment in juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2009; 60 Suppl: S233.
28. Stocco G, Cheok MH, Crews KR, Dervieux T, French D, Pei D, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 85: 164-72.
29. Dolezalova P, Krijt J, Chladek J, Nemcova D, Hoza J,. Adenosine and methotrexate polyglutamate concentrations in patients with juvenile arthritis. Rheumatology (Oxford) 2005; 44: 74-9.